628 related articles for article (PubMed ID: 28574618)
21. Investigation on acute effects of enzyme replacement therapy and influence of clinical severity on physiological variables related to exercise tolerance in patients with late onset Pompe disease.
Sechi A; Salvadego D; Da Ponte A; Bertin N; Dardis A; Cattarossi S; Devigili G; Reccardini F; Bembi B; Grassi B
Neuromuscul Disord; 2017 Jun; 27(6):542-549. PubMed ID: 28433478
[TBL] [Abstract][Full Text] [Related]
22. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
[TBL] [Abstract][Full Text] [Related]
23. Aerobic training as an adjunctive therapy to enzyme replacement in Pompe disease.
Nilsson MI; Samjoo IA; Hettinga BP; Koeberl DD; Zhang H; Hawke TJ; Nissar AA; Ali T; Brandt L; Ansari MU; Hazari H; Patel N; Amon J; Tarnopolsky MA
Mol Genet Metab; 2012 Nov; 107(3):469-79. PubMed ID: 23041258
[TBL] [Abstract][Full Text] [Related]
24. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
25. Real-life effectiveness 1 year after switching to avalglucosidase alfa in late-onset Pompe disease patients worsening on alglucosidase alfa therapy: A French cohort study.
Tard C; Bouhour F; Michaud M; Beltran S; Fournier M; Demurger F; Lagrange E; Nollet S; Sacconi S; Noury JB; Magot A; Cintas P; Renard D; Deibener-Kaminsky J; Lefeuvre C; Davion JB; Salort-Campana E; Arrassi A; Taouagh N; Spinazzi M; ; Attarian S; Laforêt P
Eur J Neurol; 2024 Jul; 31(7):e16292. PubMed ID: 38587143
[TBL] [Abstract][Full Text] [Related]
26. The impact of antibodies in late-onset Pompe disease: a case series and literature review.
Patel TT; Banugaria SG; Case LE; Wenninger S; Schoser B; Kishnani PS
Mol Genet Metab; 2012 Jul; 106(3):301-9. PubMed ID: 22613277
[TBL] [Abstract][Full Text] [Related]
27. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
[TBL] [Abstract][Full Text] [Related]
28. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
[TBL] [Abstract][Full Text] [Related]
29. The impact of interrupting enzyme replacement therapy in late-onset Pompe disease.
Wenninger S; Gutschmidt K; Wirner C; Einvag K; Montagnese F; Schoser B
J Neurol; 2021 Aug; 268(8):2943-2950. PubMed ID: 33625582
[TBL] [Abstract][Full Text] [Related]
30. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
Oliveira Santos M; Evangelista T; Conceição I
Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719
[TBL] [Abstract][Full Text] [Related]
32. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
33. Vacuolated PAS-positive lymphocytes as an hallmark of Pompe disease and other myopathies related to impaired autophagy.
Pascarella A; Terracciano C; Farina O; Lombardi L; Esposito T; Napolitano F; Franzese G; Panella G; Tuccillo F; la Marca G; Bernardini S; Boffo S; Giordano A; Di Iorio G; Melone MAB; Sampaolo S
J Cell Physiol; 2018 Aug; 233(8):5829-5837. PubMed ID: 29215735
[TBL] [Abstract][Full Text] [Related]
34. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
[TBL] [Abstract][Full Text] [Related]
35. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
[TBL] [Abstract][Full Text] [Related]
36. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
Regnery C; Kornblum C; Hanisch F; Vielhaber S; Strigl-Pill N; Grunert B; Müller-Felber W; Glocker FX; Spranger M; Deschauer M; Mengel E; Schoser B
J Inherit Metab Dis; 2012 Sep; 35(5):837-45. PubMed ID: 22290025
[TBL] [Abstract][Full Text] [Related]
37. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
Han SO; Li S; Bird A; Koeberl D
Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
[TBL] [Abstract][Full Text] [Related]
38. Effect of long term enzyme replacement therapy in late onset Pompe disease: A single-centre experience.
Papadimas GK; Anagnostopoulos C; Xirou S; Michelakakis H; Terzis G; Mavridou I; Kararizou E; Papadopoulos C
Neuromuscul Disord; 2021 Feb; 31(2):91-100. PubMed ID: 33451932
[TBL] [Abstract][Full Text] [Related]
39. Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years.
Angelini C; Semplicini C; Ravaglia S; Bembi B; Servidei S; Pegoraro E; Moggio M; Filosto M; Sette E; Crescimanno G; Tonin P; Parini R; Morandi L; Marrosu G; Greco G; Musumeci O; Di Iorio G; Siciliano G; Donati MA; Carubbi F; Ermani M; Mongini T; Toscano A;
J Neurol; 2012 May; 259(5):952-8. PubMed ID: 22081099
[TBL] [Abstract][Full Text] [Related]
40. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]